[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100504013":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":26,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":26,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":26,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":26,"overallStatus":81,"whyStopped":26,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stupp Protocol","PLACEBO_COMPARATOR","Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Placebo that has the same appearance and flavor with Elemene is given 20ml orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Ele-Stupp Protocol","EXPERIMENTAL","Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Elemene is given 20ml:176mg orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.",[19],"Drug: Elemene",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Elemene","Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.",[9],[32,35],{"name":33,"affiliation":5,"role":34},"Wenbin Ma, MD","STUDY_CHAIR",{"name":36,"affiliation":5,"role":37},"Yu Wang, MD, PHD","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Yu Wang, MD, PhD","CONTACT","01069152530","ywang@pumch.cn",[45],{"facility":5,"status":26,"city":46,"state":26,"zip":26,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Beijing","China","CN",{"type":50,"coordinates":51},"Point",[52,53],116.39723,39.9075,{"lat":53,"lon":52},[56,57],{"name":40,"role":41,"phone":26,"phoneExt":26,"email":43},{"name":58,"role":41,"phone":26,"phoneExt":26,"email":59},"Xiaopeng Guo, MD","guoxiaopeng_pumch@163.com",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100504013","phase-2-elemene-plus-stupp-protocol-versus-stupp-protocol-alone-for-newly-diagnosed-glioblastoma-100504013",false,"NCT05842746","Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma","Efficacy and Safety of Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma: A Multi-center Phase II Randomized Controlled Trial","Inclusion Criteria:\n\n* newly-diagnosed supratentorial glioblastoma, IDH-wildtype, WHO grade 4\n* male or female adult patients \\\u003C 70 years old\n* Karnofsky performance status (KPS) score higher or equal to 60\n* a minimum life expectancy of 12 weeks\n* adequate bone marrow function (white blood cell ≥ 2.0 × 10\\^9\u002FL, neutrophils ≥ 1.5 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL, and platelets ≥ 100 × 10\\^9\u002FL)\n* adequate hepatic function (direct bilirubin and indirect bilirubin ≤ 1.5 mg\u002FdL, and alanine aminotransferase \\[ALT\\] and aspartate aminotransferase \\[AST\\] \\\u003C 4 times the upper limit of normal)\n* adequate renal function (creatinine \\\u003C 80 umol\u002FL)\n* adequate coagulation function (international normalized ratio \\[INR\\] ≤ 1.3)\n* voluntary to participate in this trial, complete all pre-specified treatment regimens, and complete required follow-up\n\nExclusion Criteria:\n\n* unwilling to participate or accept the pre-specified treatment regimen and required follow-up schedule\n* prior treatment (surgery, radiotherapy, chemotherapy) for glioblastoma\n* pregnant or lactating patients\n* allergic to Elemene and its components\n* severe liver and kidney dysfunction, coagulation disorders, or decreased hematopoietic ability\n* serious infection\n* serious hyperlipidaemia\n* medical illness or psychosocial circumstance that may compromise participant safety","ALL","18 Years","70 Years",{"count":73,"type":74},74,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The goal of this phase II randomized clinical trial is to compare the safety and efficacy of Elemene plus Stupp Protocol (the new protocol) and Stupp Protocol alone (the standard protocol) in patients with newly-diagnosed glioblastomas (ndGBMs). The main questions to answer are:\n\n* Whether the new treatment protocol (Elemene plus Stupp Protocol) is clinically safe for ndGBM patients.\n* Whether the new treatment protocol (Elemene plus Stupp Protocol) brings better survival benefits for ndGBM patients compared to the standard-of-care Stupp Protocol.\n\nStudy participants will be enrolled in 5 hospitals in China and randomly assigned to receive either the new protocol or the standard protocol. The overall survival (OS) rate in the 12th month, the progression-free survival (PFS) rate in the 6th month, OS, PFS, and adverse events assessed by the CTCAE (Common Terminology Criteria for Adverse Events) will be evaluated for all patients.",[80],"Glioblastoma, IDH-wildtype","NOT_YET_RECRUITING","2023-04-22",{"date":84,"type":85},"2023-05-06","ACTUAL",{"date":87,"type":74},"2023-05",{"date":89,"type":74},"2027-05",{"name":5,"class":6},1]